v3.26.1
Note 14 - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Feb. 03, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Net income (loss) - before noncontrolling interest   $ (6,598) $ (12,324) $ (7,662) $ 6,300
Net income (loss) attributable to noncontrolling interest   1,214 403 2,218 747
Net income (loss) attributable to PAVmed   (5,384) (11,921) (5,444) 7,047
Deemed dividend on Preferred Stock       (26,460)  
Net income (loss) attributable to PAVmed common stockholders   (5,479) (13,308) (12,467) 4,386
Fair Value Adjustment for diluted EPS calculation   0 0 0 249
Add back: Series C Convertible Preferred Stock dividends and deemed dividends   0 0 0 2,486
Net income (loss) attributable to PAVmed common stockholders used in dilutive EPS calculation   $ (5,479) $ (13,308) $ (12,467) $ 7,121
Weighted average common shares outstanding, basic (in shares)   6,269,384 602,822 3,938,037 533,068
Add: Restricted stock awards (in shares)   0 0 0 10,764
Add: Senior Convertible Note (in shares)   0 0 0 574,126
Add: Series C Convertible Preferred Stock (in shares)   0 0 0 691,141
Weighted average common shares outstanding, diluted (in shares)   6,269,384 602,822 3,938,037 1,809,099
Net income (loss) per share attributable to PAVmed common stockholders, basic (in dollars per share)   $ (0.87) $ (22.08) $ (3.17) $ 8.23
Net income (loss) per share attributable to PAVmed common stockholders, diluted (in dollars per share)   $ (0.87) $ (22.08) $ (3.17) $ 3.94
Series B Preferred Stock [Member]          
Preferred Stock dividends – earned   $ (95) $ (88) $ (189) $ (175)
Series C Preferred Stock [Member]          
Preferred Stock dividends – earned $ (145) 0 (481) (145) (879)
Deemed dividend on Preferred Stock   $ 0 $ (818) $ (6,689) $ (1,607)